A phase II study of capecitabine, oxaliplatin, and bevacizumab for metastatic or unresectable neuroendocrine tumors.

Kunz, P. L.; Kuo, Tai Chih; Zahn, Jeffrey; Kaiser, H. L.; Norton, Jeffrey A.; Visser, B. C.; Longacre, Teri A.; Ford, JM; Balise, Raymond R.; Fisher, George A.

doi:10.1200/jco.2010.28.15_suppl.4104

Cited by 41 publications

(25 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the second trial presented at ASCO, a phase II trial by Kunz et al [29], the efficacy of bevacizumab in combination with oxaliplatin and capecitabine was assessed in 40 patients with biopsy-proven metastatic or unresectable GET-NETs. Primary endpoints were PFS and toxicity; secondary end points were overall survival and response rates.…”

Section: Bevacizumabmentioning

confidence: 99%

Therapy innovations: tyrosine kinase inhibitors for the treatment of pancreatic neuroendocrine tumors

Raymond

Hobday

Castellano

et al. 2011

Cancer Metastasis Rev

View full text Add to dashboard Cite

Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) show limited sensitivity to cytotoxic agents, requiring the search for novel therapies. Recently, data from a phase III trial demonstrated that sunitinib produces a clinically significant improvement in progression-free survival in patients with unresectable, advanced, or metastatic GEP-NETs. Based on this finding, sunitinib became the first targeted drug approved for the treatment of GEP-NETs, paving the way for the approval of other anticancer agents in this drug-orphan disease. To date, results of trials involving other multitargeted tyrosine kinase inhibitors, such as sorafenib, the monoclonal antibody bevacizumab, and insulin-like growth factor 1 receptor inhibitors, have also shown promising results, and some are already being studied in phase III trials. This review updates the results of ongoing trials using inhibitors of growth factors and tyrosine kinase receptors involved in the carcinogenesis of GEP-NETs.

show abstract

Section: Bevacizumabmentioning

confidence: 99%

Therapy innovations: tyrosine kinase inhibitors for the treatment of pancreatic neuroendocrine tumors

Raymond

Hobday

Castellano

et al. 2011

Cancer Metastasis Rev

View full text Add to dashboard Cite

show abstract

“…A phase II study in combination with 2-methoxyestradiol revealed some degree of tumour reduction without achieving objective response according to RECIST response criteria (Kulke et al 2011). Bevacizumab has also been studied in phase II trials in NETs in combination with temozolomide, with higher response rates observed in pancreatic NET G2 (Chan et al 2012, Koumarianou et al 2012) and in combination with oxaliplatin and capecitabine, reaching an objective response rate of 23% (Kunz et al 2010). A randomised comparison of bevacizumab and octreotide vs IFN and octreotide is ongoing (NCT00569127).…”

Section: Inducing Angiogenesismentioning

confidence: 99%

Hallmarks of gastrointestinal neuroendocrine tumours: implications for treatment

Walenkamp¹,

Crespo²,

Maya³

et al. 2014

Endocrine-Related Cancer

View full text Add to dashboard Cite

In the past few years, there have been advances in the treatment of neuroendocrine tumours (NETs) and improvements in our understanding of NET biology. However, the benefits to patients have been relatively modest and much remains yet to be done. The 'Hallmarks of Cancer', as defined by Hanahan and Weinberg, provide a conceptual framework for understanding the aberrations that underlie tumourigenesis and to help identify potential targets for therapy. In this study, our objective is to review the major molecular characteristics of NETs, based on the recently modified 'Hallmarks of Cancer', and highlight areas that require further research.

show abstract

“…In addition, bevacizumab has been studied in multiple small phase II clinical trials in combination with chemotherapies, including CAPOX, FOLFOX, and temozolomide (39)(40)(41)(42). Despite its demonstration of clinical activity in NETs in early phase clinical trials, the efficacy has not been confirmed in a requisite prospective, randomized phase III study.…”

Section: Bevacizumab and The Angiogenic Vegf Pathwaymentioning

confidence: 99%

Biologics in gastrointestinal and pancreatic neuroendocrine tumors

Liu

Kunz

2017

J. Gastrointest. Oncol.

View full text Add to dashboard Cite

A phase II study of capecitabine, oxaliplatin, and bevacizumab for metastatic or unresectable neuroendocrine tumors.

Cited by 41 publications

References 0 publications

Therapy innovations: tyrosine kinase inhibitors for the treatment of pancreatic neuroendocrine tumors

Therapy innovations: tyrosine kinase inhibitors for the treatment of pancreatic neuroendocrine tumors

Hallmarks of gastrointestinal neuroendocrine tumours: implications for treatment

Biologics in gastrointestinal and pancreatic neuroendocrine tumors

Contact Info

Product

Resources

About